LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Ardelyx Inc

Затворен

СекторЗдравеопазване

6.6 -2.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.57

Максимум

6.82

Ключови измерители

By Trading Economics

Приходи

-37M

-38M

Продажби

-31M

94M

EPS

-0.15

Марж на печалбата

-39.805

Служители

489

EBITDA

-42M

-32M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+144.84% upside

Дивиденти

By Dow Jones

Следващи печалби

3.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

334M

1.8B

Предишно отваряне

8.82

Предишно затваряне

6.6

Настроения в новините

By Acuity

26%

74%

60 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Ardelyx Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Falls on Renewed Inflation Concerns -- Market Talk

10.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10.05.2026 г., 23:38 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10.05.2026 г., 23:14 ч. UTC

Пазарно говорене

Australia's Political Map Continues to Be Redrawn -- Market Talk

10.05.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects Deal to Close in 1Q FY27

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10.05.2026 г., 10:21 ч. UTC

Печалби

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9.05.2026 г., 06:05 ч. UTC

Печалби

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ardelyx Inc Прогноза

Ценова цел

By TipRanks

144.84% нагоре

12-месечна прогноза

Среден 16.6 USD  144.84%

Висок 19 USD

Нисък 13 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Ardelyx Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

5

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

3.62 / 3.95Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

60 / 347 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
help-icon Live chat